Minimal residual disease testing to predict relapse following transplant for AML and high-grade myelodysplastic syndromes

Expert Review of Molecular Diagnostics

Volumn 11, Issue 4, 2011, Pages 361-366

  Wertheim, Gerald B ^a   Bagg, Adam ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

acute myeloid leukemia; donor chimerism; hematopoietic stem cell transplant; high grade myelodysplastic syndrome; minimal residual disease; reduced intensity conditioning; WT1

Indexed keywords

WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; GENE EXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA RELAPSE; MINIMAL RESIDUAL DISEASE; MYELODYSPLASTIC SYNDROME; PREDICTION;

EID: 79955761927     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.11.19     Document Type: Article

References (57)

1. Swerdlow SH, Campo E, Harris NL et al. (Eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon, France (2008).
2. Lugthart S, Figueroa ME, Bindels E et al. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood 117, 234-241 (2011).
3. Mardis ER, Ding L, Dooling DJ et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058-1066 (2009).
4. Figueroa ME, Lugthart S, Li Y et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17, 13-27 (2010).
5. Valk PJ, Verhaak RG, Beijen, MA et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 350, 1617-1628 (2004). (Pubitemid 38528701)
6. Bejar R, Ebert BL. The genetic basis of myelodysplastic syndromes. Hematol. Oncol. Clin. North Am. 24, 295-315 (2010).
7. Jädersten M, Hellström-Lindberg E. New clues to the molecular pathogenesis of myelodysplastic syndromes. Exp. Cell Res. 316(8), 1390-1396 (2010).
8. Haase D, Germing U, Schanz J et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110, 4385-4395 (2007). (Pubitemid 351377805)
9. Look AT. Molecular pathogenesis of MDS. Hematology Am. Soc. Hematol. Educ. Prog. 156-160 (2005).
10. Rocquain J, Carbuccia N, Trouplin V et al. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer 10, 401 (2010).
11. Falini B, Mecucci C, Saglio G et al. NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia. Haematologica 93, 439-442 (2008). (Pubitemid 351398646)
12. Kottaridis PD, Gale RE, Langabeer SE, Frew ME, Bowen DT, Linch DC. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 100, 2393-2398 (2002).
13. Ariyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev. Mol. Med. 9, 1-17 (2007). (Pubitemid 46965072)
14. Armstrong JF, Pritchard-Jones K, Bickmore WA, Hastie ND, Bard JB. The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo. Mech. Dev. 40, 85-97 (1993).
15. Pritchard-Jones K, Fleming S, Davidson D et al. The candidate Wilms' tumour gene is involved in genitourinary development. Nature 346, 194-197 (1990).
16. Rackley RR, Flenniken AM, Kuriyan NP, Kessler PM, Stoler MH, Williams BR. Expression of the Wilms' tumor suppressor gene WT1 during mouse embryogenesis. Cell Growth Differ. 4, 1023-1031 (1993).
17. Hosen N, Shirakata T, Nishida S et al. The Wilms' tumor gene WT1-GFP knock-in mouse reveals the dynamic regulation of WT1 expression in normal and leukemic hematopoiesis. Leukemia 21, 1783-1791 (2007). (Pubitemid 47086767)
18. Maurer U, Brieger J, Weidmann E, Mitrou PS, Hoelzer D, Bergmann L. The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. Exp. Hematol. 25, 945-950 (1997). (Pubitemid 27368285)
19. Huff V. Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nat. Rev. Cancer 11, 111-121 (2011).
20. Yang L, Han Y, Suarez Saiz F, Minden MD. A tumor suppressor and oncogene: the WT1 story. Leukemia 21, 868-876 (2007). (Pubitemid 46672061)
21. Hosen N, Sonoda Y, Oji Y et al. Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells. Br. J. Haematol. 116, 409-420 (2002). (Pubitemid 34155516)
22. Inoue K, Ogawa H, Sonoda Y et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89, 1405-1412 (1997). (Pubitemid 27080005)
23. Inoue K, Sugiyama H, Ogawa H et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84, 3071-3079 (1994). (Pubitemid 24328100)
24. Cilloni D, Gottardi E, Messa F et al. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J. Clin. Oncol. 21, 1988-1995 (2003). (Pubitemid 46606388)
25. Cilloni D, Saglio G. WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Haematol. 112, 79-84 (2004). (Pubitemid 38716252)
26. Tamaki H, Ogawa H, Ohyashiki K et al. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 13, 393-399 (1999). (Pubitemid 29108078)
27. Cilloni D, Gottardi E, De Micheli D et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 16, 2115-2121 (2002). (Pubitemid 35203456)
28. Cilloni D, Renneville A, Hermitte F et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J. Clin. Oncol. 27, 5195-5201 (2009).
29. Inoue K, Ogawa H, Yamagami T et al. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 88, 2267-2278 (1996). (Pubitemid 26307931)
30. Miyawaki S, Hatsumi N, Tamaki T et al. Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia. Leuk. Lymphoma. 51, 1855-1861 (2010).
31. Nowakowska-Kopera A, Sacha T, Florek I, Zawada M, Czekalska S, Skotnicki AB. Wilms' tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring of minimal residual disease in acute leukemia. Leuk. Lymphoma 50, 1326-1332 (2009).
32. Ostergaard M, Olesen LH, Hasle H, Kjeldsen E, Hokland P. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study. Br. J. Haematol. 125, 590-600 (2004). (Pubitemid 38747961)
33. Weisser M, Kern W, Rauhut S et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 19, 1416-1423 (2005). (Pubitemid 41148947)
34. Gupta V, Tallman MS, Weisdorf DJ. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood 117, 2307-2318 (2011).
35. O'Donnell MR, Appelbaum FR, Coutre SE et al. Acute myeloid leukemia. J. Natl Compr. Canc. Netw. 6, 962-993 (2008).
36. Horwitz ME. Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemia. Curr. Opin. Oncol. 23, 197-202 (2011).
37. Mohty M, de Lavallade H, El-Cheikh J et al. Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a 'donor' versus 'no donor' comparison. Leukemia 23, 194-196 (2009).
38. Juliusson G, Karlsson K, Lazarevic VL et al. Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia: Real-World Population-Based Data From the Swedish Acute Leukemia Registry 1997-2006. Cancer DOI: 10.1002/cncr.26033 (2011) (Epub ahead of print).
39. Litzow MR, Tarima S, Perez WS et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 115, 1850-1857 (2010).
40. Candoni A, Tiribelli M, Toffoletti E et al. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Eur. J. Haematol. 82, 61-68 (2009).
41. Ogawa H, Ikegame K, Kawakami M, Tamaki H. WT1 gene transcript assay for relapse in acute leukemia after transplantation. Leuk. Lymphoma 45, 1747-1753 (2004). (Pubitemid 38997140)
42. Ogawa H, Tamaki H, Ikegame K et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 101, 1698-1704 (2003). (Pubitemid 36237562)
43. Lange T, Hubmann M, Burkhardt R et al. Monitoring of WT1 expression in PB and CD34+ donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning. Leukemia 25, 498-505 (2011).
44. Candoni A, Toffoletti E, Gallina R et al. Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia. Clin. Transplant. 25(2), 308-316 (2011).
45. Gaiger A, Schmid D, Heinze G et al. Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia. Leukemia 12, 1886-1894 (1998). (Pubitemid 28554462)
46. Hamalainen MM, Kairisto V, Juvonen V et al. Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia. Eur. J. Haematol. 80, 201-207 (2008). (Pubitemid 351253460)
47. Elmaagacli AH. Molecular methods used for detection of minimal residual disease following hematopoietic stem cell transplantation in myeloid disorders. Methods Mol. Med. 134, 161-178 (2007).
48. Hadd AG, Brown JT, Andruss BF, Ye F, WalkerPeach CR. Adoption of array technologies into the clinical laboratory. Expert Rev. Mol. Diagn. 5, 409-420 (2005). (Pubitemid 40686100)
49. Abdel-Wahab O, Mullally A, Hedvat C et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114, 144-147 (2009).
50. Aurer I, Labar B, Nemet D, Ajdukovic R, Bogdanic V, Gale RP. High incidence of conservative RAS mutations in acute myeloid leukemia. Acta Haematol. 92, 123-125 (1994).
51. Figueroa ME, Abdel-Wahab O, Lu C et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553-567 (2010).
52. Gelsi-Boyer V, Trouplin V, Adelaide J et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br. J. Haematol. 145, 788-800 (2009).
53. Jankowska AM, Szpurka H, Tiu RV et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/ myeloproliferative neoplasms. Blood 113, 6403-6410 (2009).
54. King-Underwood L, Pritchard-Jones K. Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood 91, 2961-2968 (1998). (Pubitemid 28227547)
55. Ley TJ, Ding L, Walter MJ et al. DNMT3A mutations in acute myeloid leukemia. N. Engl. J. Med. 363, 2424-2433 (2010).
56. Nikoloski G, Langemeijer SM, Kuiper RP et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat. Genet. 42, 665-667 (2010).
57. Pabst T, Mueller BU, Zhang P et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-a (C/EBPa), in acute myeloid leukemia. Nat. Genet. 27, 263-270 (2001). (Pubitemid 32201846)